This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.


24Apr 2020

Back to Seminars overview

International seminar by Greg Hannon

Greg Hannon
Cancer Research UK Cambridge Institute, United Kingdom

Lessons from studies of tumour heterogeneity

Friday, April 24, 2020
Piet Borst Auditorium, Netherlands Cancer Institute, Amsterdam

Host: Jelle Wesseling

Greg Hannon
Greg Hannon FRS FMedSci is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Research Institute at the University of Cambridge. Professor Hannon is internationally recognized for his contributions to small RNA biology, cancer biology, and mammalian genomics.  He has a long history in the discovery of cancer genes, beginning with work at CSHL that led to the identification of CDK inhibitors and their links to cancer.  More recently, his work has focused on small RNA biology, which led to an understanding of the biochemical mechanisms and biological functions of RNAi.  Building upon this foundation, he has developed widely used tools and strategies for manipulation of gene expression in mammalian cells and animals and has generated genome-wide shRNA libraries that are available to the cancer community.  He was among the first to uncover roles for microRNAs in cancer, including the discovery of the miR-17-92 cluster as an oncogene, the placement of miR-34 within the p53 pathways, and the understanding that let-7 and miR-93 are critical regulators of both normal stem cells and tumor initiating cells in several tissues.  His laboratory also discovered the piRNA pathway and linked this to transposon repression and the protection of germ cell genomes.  He has a continuous history of collaboration and technological innovation, including the development of selective re-sequencing strategies that are now being used within TCGA and the 1000 Genomes project.  

Share this page